person · Reporting owner

Washington Robin L

Disclosed activity across 6 companies

Tapewire entity: 10572
SEC CIK: 0001327145

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alphabet Inc.GOOGL · Entity 2516	Director	September 14, 2026	September 17, 2026
GILEAD SCIENCES, INC.GILD · Entity 405	EVP, CFO	February 12, 2019	March 14, 2019
HONEYWELL INTERNATIONAL INC- · Entity 2988	Director	February 18, 2025	February 20, 2025
Salesforce, Inc.CRM · Entity 2842	Director · President and COFO	September 22, 2026	September 23, 2026
Vertiv Holdings CoVRT · Entity 440	Director	November 19, 2024	November 21, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alphabet Inc.

Report date September 14, 2026 · Filed September 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class C Google Stock UnitsSEC Table I · non-derivative	Direct	941	Reported balance After 2026-09-14 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-14 · Grant · Acquired 1 · Balance 941 F1: The Google Stock Units (GSUs) entitle the Reporting Person to receive one share of Alphabet Inc. Class C Capital Stock for each share underlying the GSU as GSU vests. 1/48 of GSUs shall vest on the 25th of the month of the Grant Date, vesting 1/48 every 1 month(s) for 7 event(s); 1/48 of GSUs shall vest on the 1st of the month 7 month(s) after the Grant Date, vesting 1/48 every 1 month(s) for 41 event(s), subject to continued employment on such vesting date(s). F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F3: Consists of 1 DEUs and 940 GSUs.
Class C Google Stock UnitsSEC Table I · non-derivative	Direct	597	Reported balance After 2026-09-14 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-14 · Grant · Acquired 0.4 · Balance 597 F4: 1/48th of GSUs vested on July 25, 2023 and an additional 1/48th of GSUs will vest monthly thereafter until the GSUs are fully vested, subject to continued service on such vesting dates. F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F5: Consists of 5 DEUs and 592 GSUs.
Class C Google Stock UnitsSEC Table I · non-derivative	Direct	903	Reported balance After 2026-09-14 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2026-09-14 · Grant · Acquired 1 · Balance 903 F6: 1/48 of GSUs vests on the 25th day of each month following the grant date for 31 months and on the 1st day of each month for the following 17 months, subject to continued employment on such vesting dates. F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F7: Consists of 7 DEUs and 896 GSUs.
Class C Google Stock UnitsSEC Table I · non-derivative	Direct	1,433	Reported balance After 2026-09-14 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2026-09-14 · Grant · Acquired 1 · Balance 1,433 F8: 1/48 of GSUs will vest on the 25th day of each month following the grant date for 19 months and on the 1st day of each month for the following 29 months, subject to continued service on the Board on the applicable vesting dates. F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests. F9: Consists of 5 DEUs and 1,428 GSUs.
Class C Capital StockSEC Table I · non-derivative	Direct	32,559	Reported balance Holding disclosure · report date 2026-09-14 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 32,559

Filing footnotes · ownership attribution and instrument terms

F1: The Google Stock Units (GSUs) entitle the Reporting Person to receive one share of Alphabet Inc. Class C Capital Stock for each share underlying the GSU as GSU vests. 1/48 of GSUs shall vest on the 25th of the month of the Grant Date, vesting 1/48 every 1 month(s) for 7 event(s); 1/48 of GSUs shall vest on the 1st of the month 7 month(s) after the Grant Date, vesting 1/48 every 1 month(s) for 41 event(s), subject to continued employment on such vesting date(s).

F2: Represents the dividend equivalent units (DEUs) that accrued on the Reporting Person's GSUs held as of September 7, 2026, in connection with the cash dividend that was declared by the Issuer and distributed on September 14, 2026. These DEUs will vest on the same schedule as the GSUs on which the DEUs accrued. Each DEU entitles the Reporting Person to receive one share of Alphabet Inc. Class C capital stock for each share underlying the DEU as each DEU vests.

F3: Consists of 1 DEUs and 940 GSUs.

F4: 1/48th of GSUs vested on July 25, 2023 and an additional 1/48th of GSUs will vest monthly thereafter until the GSUs are fully vested, subject to continued service on such vesting dates.

F5: Consists of 5 DEUs and 592 GSUs.

F6: 1/48 of GSUs vests on the 25th day of each month following the grant date for 31 months and on the 1st day of each month for the following 17 months, subject to continued employment on such vesting dates.

F7: Consists of 7 DEUs and 896 GSUs.

F8: 1/48 of GSUs will vest on the 25th day of each month following the grant date for 19 months and on the 1st day of each month for the following 29 months, subject to continued service on the Board on the applicable vesting dates.

F9: Consists of 5 DEUs and 1,428 GSUs.

GILEAD SCIENCES, INC.

Report date February 12, 2019 · Filed March 14, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	21,620	Ending reported balance After 2019-02-25 transaction · row 4 3 source rows · reconciled sequence Row 1 · 2019-02-12 · Other · Disposed 11,588 · Balance 21,620 F1: Shares transferred to family trust. Row 3 · 2019-02-15 · Grant · Acquired 330 · Balance 21,950 F2: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2018 through February 15, 2019. This transaction is exempt under Rule 16b-3(c). F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2019. Row 4 · 2019-02-25 · Other · Disposed 330 · Balance 21,620 F1: Shares transferred to family trust.
Common StockSEC Table I · non-derivative	IndirectBy Trust	116,993	Reported balance After 2019-02-12 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2019-02-12 · Other · Acquired 11,588 · Balance 116,993 F1: Shares transferred to family trust.
Common StockSEC Table I · non-derivative	IndirectBy Trust	117,323	Reported balance After 2019-02-25 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2019-02-25 · Other · Acquired 330 · Balance 117,323 F1: Shares transferred to family trust.

Filing footnotes · ownership attribution and instrument terms

F1: Shares transferred to family trust.

F2: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Gilead Sciences, Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of August 16, 2018 through February 15, 2019. This transaction is exempt under Rule 16b-3(c).

F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on February 15, 2019.

HONEYWELL INTERNATIONAL INC

Report date February 18, 2025 · Filed February 20, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,041	Ending reported balance After 2025-02-18 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-02-18 · Exercise / conversion · Acquired 3,164 · Balance 3,165 F1: All options held by the Reporting Person have been adjusted to increase the number of shares and reduce the exercise price in a manner subject to the adjustment provisions of the Garrett Motion Inc. spin-off from Honeywell which occurred on October 1, 2018 and the Resideo Technologies, Inc. spin-off from Honeywell which occurred on October 29, 2018. Row 2 · 2025-02-18 · Tax withholding · Disposed 2,124 · Balance 1,041
Employee Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $97.92 · Expires 2025-04-26	Direct	0	Reported balance After 2025-02-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-02-18 · Exercise / conversion · Disposed 3,164 · Balance 0 F1: All options held by the Reporting Person have been adjusted to increase the number of shares and reduce the exercise price in a manner subject to the adjustment provisions of the Garrett Motion Inc. spin-off from Honeywell which occurred on October 1, 2018 and the Resideo Technologies, Inc. spin-off from Honeywell which occurred on October 29, 2018. F2: Represents exempt grant of non-qualified stock options under the 2006 Stock Plan for Non-Employee Directors that vest in four equal annual installments, with the first installment vesting on April 1, 2016.
Common StockSEC Table I · non-derivative	IndirectHeld in a trust	12,132	Reported balance Holding disclosure · report date 2025-02-18 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 12,132

Filing footnotes · ownership attribution and instrument terms

F1: All options held by the Reporting Person have been adjusted to increase the number of shares and reduce the exercise price in a manner subject to the adjustment provisions of the Garrett Motion Inc. spin-off from Honeywell which occurred on October 1, 2018 and the Resideo Technologies, Inc. spin-off from Honeywell which occurred on October 29, 2018.

F2: Represents exempt grant of non-qualified stock options under the 2006 Stock Plan for Non-Employee Directors that vest in four equal annual installments, with the first installment vesting on April 1, 2016.

Salesforce, Inc.

Report date September 22, 2026 · Filed September 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	49,750	Ending reported balance After 2026-09-22 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-22 · Exercise / conversion · Acquired 1,831 · Balance 50,658 Row 2 · 2026-09-22 · Tax withholding · Disposed 908 · Balance 49,750 F1: Represents shares withheld to satisfy the reporting person's tax liability upon vesting and settlement of a restricted stock unit award.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-03-22	Direct	18,310	Reported balance After 2026-09-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-09-22 · Exercise / conversion · Disposed 1,831 · Balance 18,310 F2: Restricted Stock Units convert to shares of common stock on a one-for-one basis. F3: These restricted stock units vest as to 25% of the original grant on March 22, 2026 and vest as to 1/16 of the original grant quarterly thereafter.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares withheld to satisfy the reporting person's tax liability upon vesting and settlement of a restricted stock unit award.

F2: Restricted Stock Units convert to shares of common stock on a one-for-one basis.

F3: These restricted stock units vest as to 25% of the original grant on March 22, 2026 and vest as to 1/16 of the original grant quarterly thereafter.

Vertiv Holdings Co

Report date November 19, 2024 · Filed November 21, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee Footnote	5,000	Last balance in matching sequence After 2024-11-19 transaction · row 9 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 9 source rows Row 1 · 2024-11-19 · Sale · Disposed 14 · Balance 9,986 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 2 · 2024-11-19 · Sale · Disposed 650 · Balance 9,336 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F3: The trade was executed in a series of transactions with a price range of $127.94 to $128.35, inclusive, with a weighted average price of $128.1338. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 3 · 2024-11-19 · Sale · Disposed 327 · Balance 9,009 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F4: The trade was executed in a series of transactions with a price range of $129.98 to $130.51, inclusive, with a weighted average price of $130.3515. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 4 · 2024-11-19 · Sale · Disposed 343 · Balance 8,666 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F5: The trade was executed in a series of transactions with a price range of $132.50 to $132.70, inclusive, with a weighted average price of $132.6176. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 5 · 2024-11-19 · Sale · Disposed 683 · Balance 7,983 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F6: The trade was executed in a series of transactions with a price range of $133.915 to $134.56, inclusive, with a weighted average price of $134.0396. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 6 · 2024-11-19 · Sale · Disposed 883 · Balance 7,100 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F7: The trade was executed in a series of transactions with a price range of $134.995 to $135.89, inclusive, with a weighted average price of $135.4847. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 7 · 2024-11-19 · Sale · Disposed 701 · Balance 6,399 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F8: The trade was executed in a series of transactions with a price range of $136.08 to $136.94, inclusive, with a weighted average price of $136.5568. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 8 · 2024-11-19 · Sale · Disposed 703 · Balance 5,696 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F9: The trade was executed in a series of transactions with a price range of $137.24 to $138.065, inclusive, with a weighted average price of $137.7667. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust. Row 9 · 2024-11-19 · Sale · Disposed 696 · Balance 5,000 F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024. F10: The trade was executed in a series of transactions with a price range of $138.475 to $138.92, inclusive, with a weighted average price of $138.7824. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Sold pursuant to a previously executed Rule 10b5-1 plan entered on August 19, 2024.

F2: Reported shares shown are held by the Carl and Robin Washington Revocable Trust. Carl D. Washington and Robin L. Washington are trustees of the Carl and Robin Washington Revocable Trust.

F3: The trade was executed in a series of transactions with a price range of $127.94 to $128.35, inclusive, with a weighted average price of $128.1338. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4: The trade was executed in a series of transactions with a price range of $129.98 to $130.51, inclusive, with a weighted average price of $130.3515. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F5: The trade was executed in a series of transactions with a price range of $132.50 to $132.70, inclusive, with a weighted average price of $132.6176. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F6: The trade was executed in a series of transactions with a price range of $133.915 to $134.56, inclusive, with a weighted average price of $134.0396. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F7: The trade was executed in a series of transactions with a price range of $134.995 to $135.89, inclusive, with a weighted average price of $135.4847. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F8: The trade was executed in a series of transactions with a price range of $136.08 to $136.94, inclusive, with a weighted average price of $136.5568. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F9: The trade was executed in a series of transactions with a price range of $137.24 to $138.065, inclusive, with a weighted average price of $137.7667. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F10: The trade was executed in a series of transactions with a price range of $138.475 to $138.92, inclusive, with a weighted average price of $138.7824. The reporting person undertakes to provide to Vertiv Holdings Co, any security holder of Vertiv Holdings Co, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Catalyst Partners Acquisition Corp.

Report date February 07, 2023 · Filed February 10, 2023

Section 16 reporting ended · disclosed 2023-02-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class B Ordinary SharesSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2023-02-07 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-07 · Other · Disposed 37,000 · Balance 0 F1: On January 31, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on February 7, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: On January 31, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on February 7, 2023.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 17, 2012 Filed Sep 19, 2012 23:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	6,000	$47.51	$285,060.00	Disclosure SEC source: 0001179110-12-014306 · edgar.xml · nonDerivative · entry 5 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 17, 2012 Filed Sep 19, 2012 23:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	8,750	$64.83	$567,236.25	Disclosure SEC source: 0001179110-12-014306 · edgar.xml · nonDerivative · entry 4 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 F3 · price: Sale prices reported for the transactions reported here range from $64.14 to $64.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
September 17, 2012 Filed Sep 19, 2012 23:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	8,750	$47.20	$413,000.00	Disclosure SEC source: 0001179110-12-014306 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 17, 2012 Filed Sep 19, 2012 23:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	42,500	$64.83	$2,755,147.50	Disclosure SEC source: 0001179110-12-014306 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 F3 · price: Sale prices reported for the transactions reported here range from $64.14 to $64.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
September 17, 2012 Filed Sep 19, 2012 23:34 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	42,500	$54.14	$2,300,950.00	Disclosure SEC source: 0001179110-12-014306 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,913 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 10, 2012 Filed Sep 11, 2012 22:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	9,000	$0.00 Strike: $49.81	$0.00	Disclosure SEC source: 0001179110-12-013916 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 9,000 shares Expires 2019-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
September 10, 2012 Filed Sep 11, 2012 22:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	9,000	$59.78	$538,020.00	Disclosure SEC source: 0001179110-12-013916 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 Read SEC document
September 10, 2012 Filed Sep 11, 2012 22:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	9,000	$49.81	$448,290.00	Disclosure SEC source: 0001179110-12-013916 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 30, 2012 Filed Sep 4, 2012 17:01 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	3,466	$57.48	$199,238.85	Disclosure SEC source: 0001179110-12-013608 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 F1 · kind: Pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · price: Sale prices reported for the transactions reported here range from $57.46 to $57.53. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
August 02, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	12,000	$0.00 Strike: $47.51	$0.00	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · derivative · entry 8 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 12,000 shares Expires 2020-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
August 02, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	17,500	$0.00 Strike: $47.20	$0.00	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · derivative · entry 7 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 17,500 shares Expires 2019-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document
August 02, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	12,000	$57.73	$692,756.40	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · nonDerivative · entry 6 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,879 F4 · price: Sale prices reported for the transactions reported here range from $57.60 to $58.03. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
August 02, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	12,000	$47.51	$570,120.00	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · nonDerivative · entry 5 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 02, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	17,500	$57.73	$1,010,269.75	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · nonDerivative · entry 4 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,879 F4 · price: Sale prices reported for the transactions reported here range from $57.60 to $58.03. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
August 02, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	17,500	$47.20	$826,000.00	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 01, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	3,034	$53.63	$162,710.39	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,879 Read SEC document
August 01, 2012 Filed Aug 3, 2012 20:53 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	6,500	$0.00	$0.00	Disclosure SEC source: 0001179110-12-012388 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,913 F3 · shares: Issuance of common stock upon vesting of performance share awards on August 1, 2012. Read SEC document
July 27, 2012 Filed Jul 31, 2012 17:48 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	2,888	$0.00 Strike: $38.17	$0.00	Disclosure SEC source: 0001179110-12-012020 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 2,888 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
July 27, 2012 Filed Jul 31, 2012 17:48 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	2,888	$55.35	$159,850.80	Disclosure SEC source: 0001179110-12-012020 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 Read SEC document
July 27, 2012 Filed Jul 31, 2012 17:48 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	2,888	$38.17	$110,234.96	Disclosure SEC source: 0001179110-12-012020 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 20, 2012 Filed Jul 24, 2012 21:17 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,331	$0.00 Strike: $38.17	$0.00	Disclosure SEC source: 0001179110-12-011745 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,638 Underlying: Common Stock · 4,331 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions are pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
July 20, 2012 Filed Jul 24, 2012 21:17 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	4,331	$53.26	$230,681.19	Disclosure SEC source: 0001179110-12-011745 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 F3 · price: Sale prices reported for the transactions reported here range from $53.11 to $53.83. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
July 20, 2012 Filed Jul 24, 2012 21:17 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	4,331	$38.17	$165,314.27	Disclosure SEC source: 0001179110-12-011745 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 29, 2012 Filed Jul 3, 2012 23:19 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	733	$29.02	$21,270.93	Disclosure SEC source: 0001179110-12-011186 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,413 F1 · kind: Amount of securities beneficially owned following the reported transaction includes 733 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 29, 2012. Read SEC document
April 20, 2012 Filed Apr 24, 2012 22:14 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	4,331	$0.00 Strike: $38.17	$0.00	Disclosure SEC source: 0001179110-12-007150 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,969 Underlying: Common Stock · 4,331 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
April 20, 2012 Filed Apr 24, 2012 22:14 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	4,331	$52.26	$226,352.35	Disclosure SEC source: 0001179110-12-007150 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,680 F3 · price: Sale prices reported for the transactions reported here range from $52.25 to $52.29. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
April 20, 2012 Filed Apr 24, 2012 22:14 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	4,331	$38.17	$165,314.27	Disclosure SEC source: 0001179110-12-007150 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2012 Filed Mar 20, 2012 22:26 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	7,998	$46.70	$373,536.99	Disclosure SEC source: 0001179110-12-005406 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,680 F1 · kind: Pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F2 · price: Sale prices reported for the transactions reported here range from $46.63 to $46.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
March 12, 2012 Filed Mar 15, 2012 00:02 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	7,002	$46.16	$323,212.32	Disclosure SEC source: 0001179110-12-005063 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,678 Read SEC document
March 12, 2012 Filed Mar 15, 2012 00:02 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001179110-12-005063 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,680 F1 · shares: Issuance of common stock upon vesting of performance share awards on March 12, 2012 Read SEC document
February 07, 2012 Filed Feb 10, 2012 00:25 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionNon-Qualified Stock Options (right to buy) · Derivative	23,100	$0.00 Strike: $38.17	$0.00	Disclosure SEC source: 0001179110-12-002247 · edgar.xml · derivative · entry 4 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,300 Underlying: Common Stock · 23,100 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: Pursuant to a Rule 105b-1 trading plan established by Ms. Washington on December 11, 2011. F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
February 07, 2012 Filed Feb 10, 2012 00:25 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	15,065	$55.28	$832,797.72	Disclosure SEC source: 0001179110-12-002247 · edgar.xml · nonDerivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,680 F4 · price: Sale prices reported for the transactions reported here range from $55.02 to $55.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
February 07, 2012 Filed Feb 10, 2012 00:25 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	SaleCommon Stock	9,935	$54.92	$545,604.37	Disclosure SEC source: 0001179110-12-002247 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,745 F3 · price: Sale prices reported for the transactions reported here range from $54.67 to $55.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document
February 07, 2012 Filed Feb 10, 2012 00:25 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	23,100	$38.17	$881,727.00	Disclosure SEC source: 0001179110-12-002247 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 26, 2012 Filed Jan 30, 2012 23:48 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Options (right to buy) · Derivative	90,000	$0.00 Strike: $48.59	$0.00	Disclosure SEC source: 0001179110-12-001318 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2022-01-26 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document
January 26, 2012 Filed Jan 30, 2012 23:48 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	1,371	$48.59	$66,616.89	Disclosure SEC source: 0001179110-12-001318 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,580 Read SEC document
January 26, 2012 Filed Jan 30, 2012 23:48 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	3,500	$0.00	$0.00	Disclosure SEC source: 0001179110-12-001318 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,951 F2 · shares: Issuance of common stock upon vesting of certain performance share awards. Read SEC document
November 07, 2011 Filed Nov 9, 2011 22:51 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionRestricted Stock Unit · Derivative	3,000	$0.00	$0.00	Disclosure SEC source: 0001179110-11-015010 · edgar.xml · derivative · entry 3 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units have a five year vesting schedule. 20% of the restricted stock units granted vest on November 5, 2011, the first anniversay of the grant. The remaining shares will vest 20% every year thereafter until fully vested on November 5, 2015. Vested shares will be delivered to the Reporting Person no later than the later of (i) the close of the calendar year in which the restricted stock units vest or (ii) the fifteenth day of the third calendar month following such vesting date. F2 · derivative.expiration_date: The restricted stock units have a five year vesting schedule. 20% of the restricted stock units granted vest on November 5, 2011, the first anniversay of the grant. The remaining shares will vest 20% every year thereafter until fully vested on November 5, 2015. Vested shares will be delivered to the Reporting Person no later than the later of (i) the close of the calendar year in which the restricted stock units vest or (ii) the fifteenth day of the third calendar month following such vesting date. Read SEC document
November 07, 2011 Filed Nov 9, 2011 22:51 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	1,100	$41.08	$45,188.00	Disclosure SEC source: 0001179110-11-015010 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,451 Read SEC document
November 07, 2011 Filed Nov 9, 2011 22:51 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Exercise / conversionCommon Stock	3,000	$0.00	$0.00	Disclosure SEC source: 0001179110-11-015010 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Amount of securities beneficially owned includes 577 shares acquired on June 30, 2010 and 732 shares acquired on June 30, 2011 under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Read SEC document
January 20, 2011 Filed Jan 25, 2011 00:46 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Options (right to buy) · Derivative	92,400	$0.00 Strike: $38.17	$0.00	Disclosure SEC source: 0001179110-11-001269 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,400 Underlying: Common Stock · 92,400 shares Expires 2021-01-20 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on January 20, 2012 the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested on January 20, 2015. The options expire on January 20, 2021. Read SEC document
November 05, 2010 Filed Nov 10, 2010 02:21 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantRestricted Stock Units · Derivative	15,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001179110-10-015799 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2015-11-05 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: The restricted stock units have a five year vesting schedule. 20% of the restricted stock units vest on November 5, 2011, the first anniversary of the grant. The balance will vest 20% every year thereafter until fully vested on November 5, 2015. Vested shares will be delivered to the Reporting Person no later than the later of (i) the close of the calendar year in which the restricted stock units vest or (ii) the fifteenth day of the third calendar month following such vesting date. Read SEC document
January 28, 2010 Filed Feb 2, 2010 00:26 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Options (right to buy) · Derivative	48,000	$0.00 Strike: $47.51	$0.00	Disclosure SEC source: 0001179110-10-001749 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2020-01-28 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 28, 2011 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 28, 2015. Read SEC document
January 28, 2010 Filed Feb 6, 2010 00:56 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	1,929	$47.51	$91,646.79	Disclosure SEC source: 0001179110-10-002239 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,242 Read SEC document
January 28, 2010 Filed Feb 6, 2010 00:56 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001179110-10-002239 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,171 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on January 28, 2010. Read SEC document
July 29, 2009 Filed Jul 31, 2009 21:23 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Options (right to buy) · Derivative	30,000	$0.00 Strike: $49.81	$0.00	Disclosure SEC source: 0001179110-09-011409 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-07-29 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on July 29, 2010 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on July 29, 2014. Read SEC document
January 21, 2009 Filed Jan 24, 2009 02:20 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Options (right to buy) · Derivative	50,000	$0.00 Strike: $47.20	$0.00	Disclosure SEC source: 0001179110-09-001498 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2019-01-21 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 21, 2010 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 21, 2014. Read SEC document
December 15, 2008 Filed Dec 18, 2008 00:37 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	Tax withholdingCommon Stock	1,787	$45.03	$80,468.61	Disclosure SEC source: 0001179110-08-021132 · edgar.xml · nonDerivative · entry 2 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,213 Read SEC document
December 15, 2008 Filed Dec 18, 2008 00:37 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	5,000	$0.00	$0.00	Disclosure SEC source: 0001179110-08-021132 · edgar.xml · nonDerivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on December 15, 2008. Read SEC document
May 07, 2008 Filed May 9, 2008 20:35 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-qualified Stock Options (right to buy) · Derivative	100,000	$0.00 Strike: $54.14	$0.00	Disclosure SEC source: 0001179110-08-009256 · edgar.xml · derivative · entry 1 Washington Robin L · CIK 0001327145 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2018-05-07 F1 · derivative.exercise_date: Options vest over a five year period with 20% vesting May 7, 2009, the first anniversary of the grant. The options will continue to vest in quarterly installments over the next four years, and will be fully vested on May 7, 2013. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.